**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16**
**OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2015

**Commission File Number: 001-36582**

# Auris Medical Holding AG

**(Exact name of registrant as specified in its charter)**

**Bahnhofstrasse 21**
**6300 Zug, Switzerland**
**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

| | | | |
|---|---|---|---|
| Form 20-F | X | Form 40-F | |

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

| | | | |
|---|---|---|---|
| Yes | | No | X |

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

| | | | |
|---|---|---|---|
| Yes | | No | X |

**INCORPORATION BY REFERENCE**

Exhibits 99.1 and 99.2 to this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-206710) and Form S-8 (Registration Numbers 333-198037 and 333-200805) of Auris Medical Holding AG and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Auris Medical Holding AG**

By: /s/ Thomas Meyer
Name: Thomas Meyer
Title: Chief Executive Officer

Date: November 12, 2015

**EXHIBIT INDEX**

| Exhibit Number | Description |
|---|---|
| 99.1 | Unaudited Condensed Consolidated Interim Financial Statements |
| 99.2 | Management's Discussion and Analysis of Financial Condition and Results of Operations |
| 99.3 | Press Release dated November 12, 2015 |

**Exhibit 99.1**

Unaudited Condensed Consolidated Interim Financial Statements as of September 30, 2015 and December 31, 2014 and for the Three and Nine Months Ended September 30, 2015 and 2014

Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income (Loss)
Condensed Consolidated Interim Statement of Financial Position
Condensed Consolidated Interim Statement of Changes in Equity
Condensed Consolidated Interim Statement of Cash Flows
Notes to the Condensed Consolidated Interim Financial Statements

**Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income (Loss) (unaudited)**
For the Three and Nine Months Ended September 30, 2015 and 2014 (in CHF)

| | | THREE MONTHS ENDED SEPT. 30 | | NINE MONTHS ENDED SEPT. 30 | |
|---|---|---|---|---|---|
| | | **2015** | **2014** | **2015** | **2014** |
| Research and development | | -5,884,313 | -4,686,442 | -20,865,100 | -13,036,450 |
| General and administrative | | -1,326,750 | -997,733 | -3,236,856 | -3,552,021 |
| **Operating loss** | | **-7,211,063** | **-5,684,175** | **-24,101,956** | **-16,588,471** |
| Interest income | | 12,873 | 6,023 | 23,141 | 35,908 |
| Interest expense | | -1,608 | -1,245 | -6,212 | -53,877 |
| Foreign currency exchange gains/losses, net | | 1,988,870 | 2,318,569 | -136,438 | 2,394,429 |
| **Net loss before tax and attributable to owners of the Company** | | **-5,210,928** | **-3,360,828** | **-24,221,465** | **-14,212,011** |
| **Other comprehensive income (loss):** | | | | | |
| **Items that will never be reclassified to profit or loss** | | | | | |
| Remeasurement of defined benefit liability, net of taxes of CHF 0.00 | | -3,792 | 111,550 | -232,962 | -312,261 |
| **Items that are or may be reclassified to profit or loss** | | | | | |
| Foreign currency translation differences, net of taxes of CHF 0.00 | | -40,524 | -74,115 | 16,339 | -71,298 |
| **Other comprehensive income (loss), net of taxes of CHF 0.00** | | **-44,316** | **37,435** | **-216,623** | **-383,559** |
| **Total comprehensive loss attributable to owners of the Company** | | **-5,255,244** | **-3,323,393** | **-24,438,088** | **-14,595,570** |
| **Basic and diluted loss per share** | 7 | **-0.15** | **-0.14** | **-0.76** | **-0.69** |

*The accompanying notes form an integral part of these condensed consolidated interim financial statements*

**Condensed Consolidated Interim Statement of Financial Position (unaudited)**
As of September 30, 2015 and December 31, 2014 (in CHF)

| | Note | SEPTEMBER 30, 2015 | DECEMBER 31, 2014 |
|---|---|---|---|
| **ASSETS** | | | |
| **Non-current assets** | | | |
| Property and equipment | | 247,129 | 235,427 |
| Intangible assets | | 1,482,520 | 1,482,520 |
| Deferred tax asset | | - | 32,761 |
| **Total non-current assets** | | **1,729,649** | **1,750,708** |
| | | | |
| **Current assets** | | | |
| Other receivables | | 575,954 | 542,538 |
| Prepayments | | 294,466 | 265,170 |
| Cash and cash equivalents | | 55,400,708 | 56,934,325 |
| **Total current assets** | | **56,271,128** | **57,742,033** |
| | | | |
| **Total assets** | | **58,000,777** | **59,492,741** |
| | | | |
| **EQUITY AND LIABILITIES** | | | |
| **Equity** | | | |
| Share capital | 3 | 13,717,556 | 11,604,156 |
| Share premium | | 112,645,019 | 93,861,171 |
| Foreign currency translation reserve | | -34,770 | -51,108 |
| Accumulated deficit | | -76,378,540 | -52,131,426 |
| **Total shareholders' equity attributable to owners of the Company** | | **49,949,265** | **53,282,793** |
| | | | |
| **Non-current liabilities** | | | |
| Employee benefits | | 1,758,770 | 1,410,598 |
| Deferred tax liabilities | | 327,637 | 360,398 |
| **Total non-current liabilities** | | **2,086,407** | **1,770,996** |
| | | | |
| **Current liabilities** | | | |
| Trade and other payables | | 2,822,445 | 3,234,384 |
| Accrued expenses | | 3,142,660 | 1,204,568 |
| **Total current liabilities** | | **5,965,105** | **4,438,952** |
| | | | |
| **Total liabilities** | | **8,051,512** | **6,209,948** |
| | | | |
| **Total equity and liabilities** | | **58,000,777** | **59,492,741** |

*The accompanying notes form an integral part of these condensed consolidated interim financial statements*

**Condensed Consolidated Interim Statement of Changes in Equity (unaudited)**
As of September 30, 2015 and 2014 (in CHF)

| | | ATTRIBUTABLE TO OWNERS OF THE COMPANY | | | | |
|---|---|---|---|---|---|---|
| | NOTE | SHARE CAPITAL | SHARE PREMIUM | FX TRANSLATION RESERVE | ACCUMULATED DEFICIT | TOTAL EQUITY |
| **Balance at January 1, 2014** | | **6,487,130** | **35,608,210** | **53,995** | **-33,115,689** | **9,033,646** |
| **Total comprehensive loss** | | | | | | |
| Net loss | | - | - | - | -14,212,011 | **-14,212,011** |
| Other comprehensive income/(-loss) | | - | - | -71,298 | -312,261 | **-383,559** |
| **Total comprehensive loss** | | - | - | **-71,298** | **-14,524,272** | **-14,595,570** |
| **Transactions with owners of the Company** | | | | | | |
| Capital increase from IPO | | 4,045,294 | 47,261,446 | - | - | **51,306,740** |
| Share issuance costs | | - | -682,860 | - | - | **-682,860** |
| Transaction costs | | - | -1,154,569 | - | - | **-1,154,569** |
| Conversion of convertible loans | | 1,043,180 | 12,717,655 | - | - | **13,760,835** |
| Share based payments | 5 | - | - | - | 238,203 | **238,203** |
| Share options exercised | 3 | 6,200 | 43,400 | - | - | **49,600** |
| **Balance at September 30, 2014** | | **11,581,804** | **93,793,282** | **-17,303** | **-47,401,758** | **57,956,025** |
| **Balance at January 1, 2015** | | **11,604,156** | **93,861,171** | **-51,109** | **-52,131,426** | **53,282,792** |
| Total comprehensive loss | | | | | | |
| Net loss | | - | - | - | -24,221,465 | **-24,221,465** |
| Other comprehensive income/(-loss) | | - | - | 16,339 | -232,962 | **-216,623** |
| **Total comprehensive loss** | | - | - | **16,339** | **-24,454,427** | **-24,438,088** |
| **Transactions with owners of the Company** | | | | | | |
| Capital increase from follow-on offering | | 2,110,000 | 19,604,877 | - | - | **21,714,877** |
| Transaction costs | | - | -643,796 | - | - | **-643,796** |
| Share issuance costs | | - | -210,826 | - | - | **-210,826** |
| Share based payments | 5 | - | - | - | 207,313 | **207,313** |
| Share options exercised | 3 | 3,400 | 33,593 | - | - | **36,993** |
| **Balance at September 30, 2015** | | **13,717,556** | **112,645,019** | **-34,770** | **-76,378,540** | **49,949,265** |

*The accompanying notes form an integral part of these condensed consolidated interim financial statements*

**Condensed Consolidated Interim Statement of Cash Flows (unaudited)**
For the Nine Months Ended September 30, 2015 and 2014 (in CHF)

| | Note | NINE MONTHS ENDED SEPTEMBER 30, 2015 | NINE MONTHS ENDED SEPTEMBER 30, 2014 |
|---|---|---|---|
| **Cash flows from operating activities** | | | |
| **Net loss** | | **-24,221,465** | **-14,212,011** |
| Adjustments for: | | | |
| Depreciation | | 68,217 | 53,291 |
| Unrealized net foreign currency exchange gain/(loss) | | 168,232 | -2,462,886 |
| Net interest (income)/expense | | -22,969 | 13,727 |
| Share option compensation | 5 | 207,313 | 238,202 |
| Employee benefits | | 115,211 | -13,338 |
| Changes in: | | | |
| Other receivables | | -33,428 | -187,147 |
| Prepayments | | -29,296 | -150,258 |
| Trade and other payables | | -411,937 | 2,658,211 |
| Accrued expenses | | 1,938,089 | -301,141 |
| **Changes in net working capital** | | **1,463,428** | **2,019,665** |
| **Cash used in operating activities** | | **-22,222,033** | **-14,363,350** |
| **Cash flows from investing activities** | | | |
| Purchase of property and equipment | | -79,917 | -102,746 |
| Interest received | | 22,969 | 35,908 |
| **Net cash used in investing activities** | | **-56,948** | **-66,838** |
| **Cash flows from (used in) financing activities** | | | |
| Proceeds from share capital increase | | 36,993 | 49,600 |
| Share issuance costs | | -210,826 | -682,860 |
| Proceeds from IPO, net | | - | 50,698,334 |
| Proceeds from follow-on offering, net | | 21,071,081 | - |
| **Net cash from (used in) financing activities** | | **20,897,248** | **50,065,074** |
| **Net increase (decrease) in cash and cash equivalents** | | **-1,381,733** | **35,634,886** |
| Cash and cash equivalents at beginning of the period | | 56,934,325 | 23,865,842 |
| Net effect of currency translation on cash | | -151,885 | 2,391,932 |
| **Cash and cash equivalents at end of the period** | | **55,400,707** | **61,892,660** |

*The accompanying notes form an integral part of these condensed consolidated interim financial statements*

## 1. Reporting entity

Auris Medical Holding AG (the "Company") is domiciled in Switzerland. The Company's registered address is at Bahnhofstrasse 21, 6300 Zug. These condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the "Group" and individually as "Group entities"). The Company is the ultimate parent of the following Group entities:

- Auris Medical AG, Basel, Switzerland (100%)
- Otolanum AG, Zug, Switzerland (100%)
- Auris Medical Inc., Chicago, United States (100%)
- Auris Medical Ltd., Dublin, Ireland (100%)

The Group is primarily involved in the development of pharmaceutical products for the treatment of inner ear disorders, in particular tinnitus and hearing loss. Its most advanced projects are in the late stage of clinical development.

## 2. Basis of preparation

*Statement of compliance*

These condensed consolidated interim financial statements as of September 30, 2015 and for the three and nine months ended September 30, 2015 and the condensed consolidated financial statements as of December 31, 2014 have been prepared in accordance with International Accounting Standard *Interim Financial Reporting* ("IAS 34") and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2014.

These condensed consolidated interim financial statements include all adjustments, that are necessary to fairly state the results of the interim period and the Group believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. Management does not consider the business to be seasonal or cyclical.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board, have been condensed or omitted as permitted by IAS 34. The condensed consolidated statement of financial position as of December 31, 2014 was derived from the audited consolidated financial statements.

The interim financial statements were authorized for issuance by the Company's Audit Committee on November 9, 2015.

*Functional and reporting currency*

These condensed consolidated financial statements are presented in Swiss Francs ("CHF"), which is the Company's functional currency ("functional currency") and the Group's reporting currency.

*Segment reporting*

A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group's other components. Management has determined that there is only one operating segment under the requirements of IFRS 8 ("Operating Segments").

*Significant accounting policies*

The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its audited consolidated financial statements as of and for the year ended December 31, 2014 and have been applied consistently to all periods presented in these condensed consolidated interim financial statements, unless otherwise indicated.

*New standards, amendments and interpretations adopted by the Group*

The Group has not early adopted any standard, interpretation or amendment that was issued, but is not yet effective.

A number of new standards, amendments to standards and interpretations are effective for the Group's 2015 reporting year, and have not been applied in preparing these condensed consolidated interim financial statements. Management does not believe that the adoption of these standards, interpretations, or amendments will have a material impact on the financial statements of the Group.

## 3. Capital and reserves

*Share capital*

The issued share capital of the Company consisted of:

| | Common Shares (Number) | | Preferred Shares (Number) | |
|---|---|---|---|---|
| | 2015 | 2014 | 2015 | 2014 |
| As of January 1 | 29,010,391 | 72,600 | — | 16,145,225 |
| Common shares issued for stock option exercises with a nominal value of CHF 0.40 each | 8,500 | 15,500 | — | — |
| Preferred shares "C" issued for conversion of convertible loan with a nominal value of CHF 0.40 each | — | — | — | 2,607,950 |
| Common shares issued for the IPO with a nominal value of CHF 0.40 each | — | 10,113,235 | — | — |
| Common shares resulting from conversion of Preferred Shares at the time of the IPO with a nominal value of CHF 0.40 each | — | 18,753,175 | — | -18,753,175 |
| Common shares issued for the follow-on offering with a nominal value of CHF 0.40 each | 5,275,000 | — | — | — |
| **Total, as of September 30** | **34,293,891** | **28,954,510** | **—** | **—** |

All shares have a nominal value of CHF 0.40 and are fully paid in. As of September 30, 2015, the nominal value of the 34,293,891 issued shares amounted to CHF 13,717,556 (as of December 31, 2014, the nominal value of 29,010,391 issued shares amounted to CHF 11,604,156).

*Issue of common shares upon exercise of options*

During the nine months ended September 30, 2014, three beneficiaries of the Option Plan A exercised their right to acquire common shares of the Company at CHF 3.20 per share. This resulted in an increase in the number of outstanding common shares of 15,500 and an increase in the share capital of CHF 6,200. Total proceeds from the exercise to the Company were CHF 49,600.

During the nine months ended September 30, 2015, beneficiaries of the Option Plan A exercised their right to acquire common shares of the Company at CHF 3.20 per share. This resulted in an increase in the number of outstanding common shares of 8,500 and an increase in the share capital of CHF 3,400. Total proceeds from the exercise to the Company were CHF 27,200. The Company also recorded the difference of CHF 9,793 between the exercise price and market price at the day of exercise in the share premium.

*Follow-On Offering on NASDAQ Global Market*

On May 20, 2015, the Company completed a public offering of 5,275,000 shares, yielding net proceeds after underwriting discounts of USD 23.6 million (CHF 21.7 million). Following the offering (and settlement of the aforementioned employee options) there were 34,293,891 common shares of the Company outstanding.

*IPO on NASDAQ Global Market*

In August 2014, the Company completed its Initial Public Offering ("IPO") issuing 10,113,235 shares, including the underwriter's overallotment option, yielding total net proceeds of CHF 51.3 million (USD 56.4 million). Following the IPO there were 28,954,510 common shares of the Company outstanding. At December 31, 2014 there were 29,010,391 shares outstanding following the exercise of options.

Pursuant to agreements with holders of preferred shares, all preferred shares outstanding at the time of the IPO converted automatically into common shares at the ratio of 1:1 upon consummation of the IPO.

*Issuance of preferred shares*

In January 2014, a convertible loan was converted into 2,607,950 preferred shares Series C with a nominal value of CHF 0.40 at a conversion price of CHF 5.28 each.

**4. Employee benefits**

| | Nine months ended September 30, 2015 | Nine months ended September 30, 2014 |
|---|---|---|
| Salaries | 1,920,616 | 1,542,359 |
| Pension costs | 239,247 | 89,612 |
| Other social benefits | 141,745 | 128,315 |
| Share based compensation expense | 207,313 | 238,202 |
| Other | 22,692 | 59,334 |
| **Total employee benefits** | **2,531,613** | **2,057,822** |

**5. Share based compensation expense**

Share based compensation expense of CHF 207,313 was recognized during the nine month period ended September 30, 2015 (for the nine months ended September 30, 2014: CHF 238,202). A total of 234,750 options were granted in the nine month period ended September 30, 2015. The exercise price of the options granted was the average closing price in the 30 days preceding the grant date, which was USD 5.98 for 95,750 options granted in March 2015 and USD 4.68 for 139,000 options granted in September 2015. The methodology for computation of share based compensation expense for the period is consistent with the methodology used in 2014.

**6. Loss per share**

| | Three months ended September 30, | | Nine months ended September 30, | |
|---|---|---|---|---|
| | **2015** | **2014** | **2015** | **2014** |
| Loss attributable to owners of the Company | (5,210,928) | (3,360,828) | (24,221,465) | (14,212,011) |
| Weighted average number of shares outstanding | 34,290,141 | 24,589,852 | 31,828,984 | 20,488,392 |
| **Basic and diluted loss per share** | (0.15) | (0.14) | (0.76) | (0.69) |

For the nine months ended September 30, 2015 and September 30, 2014 basic and diluted loss per share is calculated based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the stock option plans, as they would be anti-dilutive. As of the date hereof, the Company has 645,260 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2015 and September 30, 2015 was 527,885 (262,500 for the period between January 1, 2014 and September 30, 2014). The average number of options outstanding between June 30, 2015 and September 30, 2015 was 575,760 (311,250 for the period between June 30, 2014 and September 30, 2014).

**Exhibit 99.2**

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited condensed consolidated interim financial statements as of and for the three and nine month periods ended September 30, 2014 and 2015 included as Exhibit 99.1 to this Report on Form 6-K, which have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting*. We also recommend that you read our management's discussion and analysis and our audited consolidated financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2014 (the "Annual Report") filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to the U.S. Securities and Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, all references to "Auris Medical" or the "company," "we," "our," "ours," "us" or similar terms refer to Auris Medical AG and its subsidiaries prior to the completion of our corporate reorganization in connection with our initial public offering, and Auris Medical Holding AG and its subsidiaries as of the completion of our corporate reorganization and thereafter.

We prepare and report our consolidated financial statements and financial information in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (the "IASB"). None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States. We maintain our books and records in Swiss Francs. We have made rounding adjustments to some of the figures included in this management's discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them. Unless otherwise indicated, all references to currency amounts in this discussions and analysis are in Swiss Francs.

This discussion and analysis is dated as of November 12, 2015.

### Overview

We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidate, AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the FDA. In two Phase 2 clinical trials, AM-101 demonstrated a favorable safety profile and statistically significant improvement in tinnitus loudness and other patient reported outcomes. We expect to have first top-line Phase 3 clinical data for AM-101 in the second quarter of 2016. We are also developing AM-111 for acute inner ear hearing loss. We are preparing two pivotal Phase 3 clinical trials in the treatment of idiopathic sudden sensorineural hearing loss, or ISSNHL, titled HEALOS and ASSENT. We expect to start enrollment in HEALOS in the fourth quarter of 2015 and in ASSENT in the first half of 2016. In addition, we are preparing a Phase 2 trial titled REACH in order to test AM-111 in the treatment of cochlear implantation surgery-induced hearing loss. We intend to seek grant funding for REACH and expect to start enrollment for the trial in the third quarter of 2016. Both acute inner ear tinnitus and hearing loss are conditions for which there is high unmet medical need, and we believe that we have the potential to be the first to market in these indications.

To date, we have financed our operations through public offerings of our common shares, private placements of equity securities and short term loans. We have no products approved for commercialization and have never generated any revenues from royalties or product sales. As of September 30, 2015, we had cash and cash equivalents of CHF 55.4 million. Based on our current plans, we do not expect to generate royalty or product revenues unless and until we obtain marketing approval for, and commercialize AM-101, AM-111 or any of our other product candidates.

Since inception, we have incurred significant operating losses. We incurred net losses (defined as net losses attributable to the owners of the Company) of CHF 18.2 million and CHF 15.0 million for the years ended December 31, 2014 and 2013, respectively. As of September 30, 2015, we had an accumulated deficit of CHF 76.4 million. We expect to continue incurring losses as we continue our clinical and pre-clinical development programs, apply for marketing approval for our product candidates and, subject to obtaining regulatory approval of our product candidates, build a sales and marketing force in preparation for the potential commercialization of our product candidates.

On May 20, 2015, we completed a public offering of common shares pursuant to a Registration Statement on Form F-1, as amended (Registration No. 333-203554). Under the registration statement, we sold an aggregate of 5,275,000 common shares at a price to the public of US$4.75 per share. The underwriting discounts and offering expenses totaled US$ 0.7 million. The offering expenses included SEC registration fees, FINRA filing fees, Nasdaq listing fees and expenses, legal fees and expenses, printing expenses, transfer agent fees and expenses, accounting fees and expenses, as well as other miscellaneous fees and expenses. In addition to offering expenses, the proceeds of the offering were subject to 1% stamp duty taxes. The net proceeds of the public offering after underwriting discounts were US$23.6 million (CHF 21.7 million).

On September 1, 2015, we filed a shelf registration statement on Form F-3 (333-206710) with the SEC to register for one or more offerings of common shares, senior debt securities, subordinated debt securities, warrants, purchase contracts or units with a maximum aggregate offering price of up to US$ 100 million. The shelf registration statement was declared effective on September 10, 2015.

There have been no developments in the previously disclosed patent interference involving our issued patent No. 9,066,865 and Otonomy Inc.'s patent application No. 13/848,636.

**Collaboration and License Agreements**

There have been no material changes to our collaboration and license agreements from those reported in "Item 5—Operating and Financial Review and Prospects–Operating results—Collaboration and License Agreements" in the Annual Report.

**Research and Development Expense**

Our research and development expense is highly dependent on the development phases of our research projects and therefore may fluctuate substantially from period to period. Our research and development expense mainly relates to the following key programs:

- AM-101. We are conducting a Phase 3 program comprising two pivotal Phase 3 clinical trials (TACTT2 and TACTT3) as well as two open label extension studies (AMPACT1 and AMPACT2). We expect first top-line data from the TACTT trials in the second quarter of 2016. We anticipate that our research and development expenses in connection with these clinical trials will be substantially higher in 2015 than in the previous financial year.

- AM-111. We are preparing two pivotal Phase 3 clinical trials in the treatment of idiopathic sudden sensorineural hearing loss, or ISSNHL, titled HEALOS and ASSENT. We expect to start enrollment in HEALOS in the fourth quarter of 2015 and in ASSENT in the first half of 2016. In addition, we are preparing a Phase 2 trial titled REACH in order to test AM-111 in the treatment of cochlear implant surgery-induced hearing loss. We intend to seek grant funding for REACH and expect to start enrollment in the third quarter of 2016. We anticipate that our research and development expenses will increase substantially in connection with commencement of these clinical trials.

- Other development programs. Other research and development expenses mainly relate to our pre-clinical studies with AM-102 and AM-123, including costs for production of the pre-clinical compounds and costs paid to academic research institutions in conjunction with pre-clinical testing.

For a discussion of our other key financial statement line items, please see "Item 5—Operating and Financial Review and Prospects–Operating results—Financial Operations Overview" in the Annual Report.

**Results of Operations**

The numbers below have been derived from our unaudited condensed consolidated interim financial statements as of and for the three and nine month periods ended September 30, 2015 and 2014. The discussion below should be read along with this financial information, and it is qualified in its entirety by reference to them.

***Comparison of three months ended September 30, 2015 and 2014***

| | Three months ended September 30, | | |
|---|---|---|---|
| | **2015** | **2014** | **Change** |
| | **(in thousands of CHF)** | | **%** |
| Research and development | (5,884) | (4,686) | 26% |
| General and administrative | (1,327) | (998) | 33% |
| **Operating loss** | **(7,211)** | **(5,684)** | **27%** |
| Finance income/(expense), net | 2,000 | 2,323 | (14)% |
| **Net loss before tax and attributable to owners of the Company** | **(5,211)** | **(3,361)** | **55%** |

***Research and development expense***

| | Three months ended September 30, | | |
|---|---|---|---|
| | **2015** | **2014** | **Change** |
| | **(in thousands of CHF)** | | **%** |
| Clinical projects | (4,292) | (3,396) | 26% |
| Pre-clinical projects | (84) | (15) | 458% |
| Drug manufacturing and substance | (570) | (571) | 0% |
| Employee benefits | (538) | (412) | 31% |
| Other research and development expenses | (401) | (292) | 37% |
| **Total** | **(5,884)** | **(4,686)** | **26%** |

Research and development expense increased 26% from CHF 4.7 million in the three months ended September 30, 2014 to CHF 5.9 million in the three months ended September 30, 2015. The variance in expense between the three months ended September 30, 2015 and the corresponding period in 2014 is mainly due to the following:

- *Clinical projects.* In the three months ended September 30, 2015 we incurred higher clinical expenses than in the three months ended September 30, 2014, primarily due to higher service and milestone costs charged by contracted service providers in connection with the late stage AM-101 clinical trials, reflecting a higher number of enrolled patients when compared with the previous reporting period and trial progress. We also incurred higher costs as a result of payments for the initiation of our AM-111 Phase 3 HEALOS trial.

- *Pre-clinical projects*. In the three months ended September 30, 2015, pre-clinical expenses increased primarily due to expenses related to our AM-102 pre-clinical project.

- *Drug manufacture and substance.* In the three months ended September 30, 2015, we incurred generally the same amount of costs as in the three months ended September 30, 2014. Such costs typically depend on the timing of raw material purchases and the manufacture of clinical trial supplies.

- *Employee benefits*. Employee expenses were higher in the three months ended September 30, 2015 than in the same period 2014 due to a higher headcount.

*General and administrative expense*

General and administrative expense was CHF 1.3 million in the three months ended September 30, 2015 compared to CHF 1.0 million in the three months ended September 30, 2014, as a result of higher administration costs (CHF 0.8 million vs 0.5 million).

We expect that general and administrative expense will increase in the future as our business expands and we continue to incur costs associated with operating as a public company and protecting our intellectual property portfolio.

*Finance income/ expense net*

Net finance income/expense decreased from CHF 2.3 million in the three months ended September 30, 2014 to CHF 2.0 million in the three month ended September 30, 2015 due to lower unrealized foreign currency exhange gains (CHF 2.1 million gain vs CHF 2.3 million gain) and higher realized foreign exchange losses (CHF 0.06 million loss vs CHF 0.03 million gain) in the three months to September 2015.

***Comparison of nine months ended September 30, 2015 and 2014***

| | Nine months ended September 30, | | |
|---|---|---|---|
| | **2015** | **2014** | **Change** |
| | **(in thousands of CHF)** | | **%** |
| Research and development | (20,865) | (13,036) | 60% |
| General and administrative | (3,237) | (3,552) | (9)% |
| **Operating loss** | **(24,102)** | **(16,588)** | **45%** |
| Finance income/(expense), net | (120) | 2,376 | (105)% |
| **Net loss before tax and attributable to owners of the Company** | **(24,221)** | **(14,212)** | **70%** |

***Research and development expense***

| | Nine months ended September 30, | | |
|---|---|---|---|
| | **2015** | **2014** | **Change** |
| | **(in thousands of CHF)** | | **%** |
| Clinical projects | (17,232) | (8,558) | 101% |
| Pre-clinical projects | (333) | (1,166) | (71)% |
| Drug manufacturing and substance | (1,058) | (1,355) | (22)% |
| Employee benefits | (1,434) | (1,210) | 18% |
| Other research and development expenses | (808) | (747) | 8% |
| **Total** | **(20,865)** | **(13,036)** | **60%** |

Research and development expense increased 60% from CHF 13.0 million in the nine months ended September 30, 2014 to CHF 20.9 million in the nine months ended September 30, 2015. The variances in expense between the nine months ended September 30, 2015 and the corresponding period in 2014 are mainly due to the following:

- *Clinical projects.* In the nine months ended September 30, 2015 we incurred significantly higher clinical expenses than in the nine months ended September 30, 2014, primarily due to higher service and milestone costs charged by contracted service providers in connection with the late stage AM-101 clinical trials, reflecting higher patient enrollment rates when compared with the previous reporting period and trial progress. We also incurred higher costs as a result of payments for the initiation of our AM-111 Phase 3 HEALOS trial.

- *Pre-clinical projects*. In the nine months ended September 30, 2015, pre-clinical expenses decreased primarily due to fewer ongoing pre-clinical studies.

- *Drug manufacture and substance.* In the nine months ended September 30, 2015, we incurred lower costs primarily due to fluctuations in the timing of raw material purchases and the manufacture of clinical trial supplies.

- *Employee benefits*. Employee expenses increased in the nine months ended September 30, 2015 compared to the same period in 2014 due to an increase in headcount.

*General and administrative expense*

General and administrative expense decreased 9% from CHF 3.6 million in the nine months ended September 30, 2014 to CHF 3.2 million in the nine months ended September 30, 2015. While employee costs increased over the previous reporting period, administration expenses decreased from CHF 2.4 million to CHF 1.8 million as substantial costs incurred in connection with preparations for our initial public offering (legal and auditing expenses) were expensed in the nine months ended September 30, 2014.

We expect that general and administrative expense will increase in the future as our business expands and we continue to incur costs associated with operating as a public company and protecting our intellectual property portfolio.

*Finance income/expense net*

Net finance income/expense decreased from an income of CHF 2.4 million in the nine months ended September 30, 2014 to an expense of CHF 0.1 million in the nine months ended September 30, 2015 due to substantially higher unrealized foreign currency exchange gains (CHF 2.4 million gain vs CHF 0.2 million loss ) partially offset by a non-cash interest charge (CHF 0.05 million) for our convertible bond in the nine months to September 2014.

**Cash flow**

***Comparison of nine months ended September 30, 2015 and 2014***

The table below summarizes our consolidated statement of cash flows for the nine months ended September 30, 2015 and 2014:

| | Nine months ended September 30, | |
|---|---|---|
| | **2015** | **2014** |
| | **(in thousands of CHF)** | |
| Cash used in operating activities | (22,222) | (14,363) |
| Net cash used in investing activities | (57) | (67) |
| Net cash from financing activities | 20,897 | 50,065 |
| Net effect of currency translation on cash | (151) | 2,392 |
| Cash and cash equivalents at beginning of the period | 56,934 | 23,866 |
| **Cash and cash equivalents at end of the period** | **55,401** | **61,893** |

The increase in cash used in operating activities from CHF 14.4 million in the nine months ended September 30, 2014 to CHF 22.2 million in the nine months ended September 30, 2015, was mainly due to higher research and development expenses and a decrease in net working capital (higher accrued expenses more than offset a decrease in payables).

Net cash used in investing activities decreased in the nine months ended September 30, 2015 due to lower expenditures for purchases of equipment and lower interest income.

Net cash from financing activities of CHF 20.9 million in the nine months ended September 30, 2015 represents proceeds from our public offering of 5,275,000 common shares at a price of US$4.75 per share. These proceeds were partially offset by issuance costs associated with the offering. In the nine months ended September 30, 2014 net cash from financing activities was CHF 50.0 million reflecting the net effect of proceeds from our initial public offering in August 2014.

***Cash and funding sources***

As of September 30, 2015, we had no long term debt and had no ongoing material financial commitments, such as lines of credit or guarantees that are expected to affect our liquidity over the next five years, other than leases.

***Funding requirements***

We believe that after the closing of our public offering on May 20, 2015, our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements at least until fall 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:

- the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities;
- the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;
- the number and characteristics of product candidates that we pursue;
- the cost, timing, and outcomes of regulatory approvals;
- the cost and timing of establishing sales, marketing, and distribution capabilities; and
- the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder.

We expect that we will require additional capital to commercialize our product candidates AM-101 and AM-111. If we receive regulatory approval for AM-101 or AM-111, and if we choose not to grant any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

We may raise additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares.

For more information as to the risks associated with our future funding needs, see “Item 3—Key Information—Risk factors” in the Annual Report.

**Contractual Obligations and Commitments**

There have been no material changes to our contractual obligations outside the ordinary course of our business from those reported in “Item 5—Operating and Financial Review and Prospects—Tabular disclosure of contractual obligations” in the Annual Report.

**Off-Balance Sheet Arrangements**

As of the date of this discussion and analysis, we do not have any, and during the periods presented we did not have any, off-balance sheet arrangements except for the Operating Lease mentioned in “Item 5—Operating and Financial Review and Prospects—Tabular disclosure of contractual obligations” in the Annual Report.

**Significant Accounting Policies and Use of Estimates and Judgment**

There have been no material changes to the significant accounting policies and estimates described in “Item 5—Operating and Financial Review and Prospects–Operating results—Significant accounting policies and use of estimates and judgment” in the Annual Report.

**Recent Accounting Pronouncements**

Except for IFRS 9 which we have not adopted yet, there are no IFRS standards as issued by the IASB or interpretations issued by the IFRS interpretations committee that are effective for the first time for the financial year beginning on or after January 1, 2015 that would be expected to have a material impact on our financial position.

**JOBS Act Exemption**

On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an “emerging growth company”. As an emerging growth company, we are not required to provide an auditor attestation report on our system of internal controls over financial reporting. This exemption will apply for a period of five years following the completion of our initial public offering (2019) or until we no longer meet the requirements of being an “emerging growth company,” whichever is earlier. We would cease to be an emerging growth company if we have more than US$1.0 billion in annual revenue, have more than US$700 million in market value of our common shares held by non-affiliates or issue more than US$1.0 billion of non-convertible debt over a three-year period.

**Cautionary Statement Regarding Forward Looking Statements**

Forward-looking statements appear in a number of places in this discussion and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Many of the forward-looking statements contained in this discussion and analysis can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various factors, including, but not limited to, those identified under the section entitled “Item 3—Key Information—Risk factors” in the Annual Report. These risks and uncertainties include factors relating to:

- our operation as a development stage company with limited operating history and a history of operating losses;
- our need for substantial additional funding before we can expect to become profitable from sales of our products;
- our dependence on the success of AM-101 and AM-111, which are still in clinical development and may eventually prove to be unsuccessful;
- the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates in the clinic or in the commercial stage;
- the chance our clinical trials may not be completed on schedule, or at all, as a result of factors such as delayed enrollment or the identification of adverse effects;

- uncertainty surrounding whether and when any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized;
- if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory overview;
- enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;
- the chance that we do not obtain orphan drug exclusivity for AM-111, which would allow our competitors to sell products that treat the same conditions;
- dependence on governmental authorities and health insurers establishing adequate reimbursement levels and pricing policies;
- our products may not gain market acceptance, in which case we may not be able to generate product revenues;
- our reliance on our current strategic relationships with INSERM or Xigen and the potential failure to enter into new strategic relationships;
- our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to supply or produce our product candidates; and
- other risk factors discussed under “Item 3—Key Information—Risk factors” included in the Annual Report.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

**Exhibit 99.3**

# Auris Medical News Release

## Auris Medical Holding AG Reports Third Quarter 2015 Financial Results and Provides Business Update

Zug, Switzerland, November 12, 2015 – Auris Medical Holding AG (NASDAQ: EARS) today provided an update on the Company's business and announced financial results for the third quarter ended September 30, 2015.

"Auris Medical continued to make good progress in the third quarter of 2015," commented Thomas Meyer, the Company's founder, Chairman and CEO. "Preparations for the three clinical trials in our AM-111 hearing loss program advanced well, with the first study expected to begin patient recruitment shortly. Importantly, our hearing loss program is generating considerable interest within the ENT community. At the same time, we reinforced our leadership in tinnitus research by taking our project AM-102 into the next stage of drug discovery. After several years of collaborative efforts together with our partners, we are very excited about AM-102's potential of becoming a powerful second generation tinnitus treatment."

Third Quarter and Recent Business Highlights

- Progressed with enrolment into pivotal AM-101 trials. The Phase 3 clinical program with AM-101 in acute inner ear tinnitus continued to progress. The Company expects to have first top-line Phase 3 clinical data for AM-101 in the second quarter of 2016.

- Launched HEALOS Phase 3 trial. In HEALOS, the first of two pivotal trials with AM-111 in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL; a.k.a. "sudden deafness"), the first study sites in Europe and Asia were opened, and enrolment is expected to begin shortly. HEALOS will enroll 255 patients suffering from acute severe to profound hearing loss within 72 hours from ISSNHL onset. They will be randomized to receive a single intratympanic dose of either AM-111 at 0.4 mg/mL or 0.8 mg/mL or placebo, and will be followed for three months. The primary efficacy endpoint is the improvement of pure tone hearing threshold from baseline to day 28 at the average of the three most affected contiguous test frequencies.

- Advanced preparations for ASSENT and REACH trials. Preparations for the two other planned AM-111 trials progressed further. For ASSENT, the second pivotal trial with AM-111 in ISSNHL, the design of the study protocol was completed, subject to final consultation with the FDA. The trial will be conducted primarily in North America, and is expected to begin enrolling patients in the first half of 2016. For REACH, a Phase 2 proof of concept study to assess AM-111's otoprotective effects in cochlear implant surgery induced hearing loss, the study protocol was finalized based on additional FDA feedback. Contingent on securing grant funding, the trial could be initiated in the third quarter of 2016.

- Provided medical education on acute hearing loss. In September 2015, Auris Medical organized a corporate symposium, "Rational Pharmacotherapy for Acute Hearing Loss – Recent Advances and Perspectives", at the Annual Meeting of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) in Dallas, TX. The symposium featured presentations from leading experts on hearing preservation following acute cochlear stress injury, inner ear drug delivery and the state of clinical research in acute hearing loss. The event highlighted the significant unmet medical need in the treatment of acute hearing loss, and laid out key considerations for the design of clinical trials. A Webcast of the event is available on Auris Medical's website in the "Events" section.

- Expanded research collaboration with King's College London. Auris Medical initiated a drug discovery collaboration with the Institute of Pharmaceutical Science of King's College London, which expands on earlier work by the Wolfson Centre for Age-Related Diseases at King's. Under the collaboration, King's will develop and optimize a range of specific small molecules for Auris Medical's AM-102 project. The AM-102 compounds bind to a novel, undisclosed drug target that is different from AM-101's target, and has been previously validated in collaboration with another research institution. From the AM-102 research project, Auris Medical aims to select a lead compound for further preclinical and subsequent clinical development as a second generation tinnitus treatment.

Financial Results

As of September 30, 2015, the Company had CHF 55.4 million in cash and cash equivalents. Operating expenses for the three months ended September 30, 2015 were CHF 7.2 million, with CHF 5.9 million attributable to research and development. This compares to operating expenses of CHF 5.7 million and research and development expenses of CHF 4.7 million for the same period in 2014. The Company reported a net loss for the quarter ended September 30, 2015 of CHF 5.2 million, or CHF 0.15 per share. This compares to a net loss of CHF 3.4 million, or CHF 0.14 per share, for the same period in 2014.

For the nine month period ended September 30, 2015, operating expenses were CHF 24.1 million, with CHF 20.9 million attributable to research and development. This compares to operating expenses of CHF 16.6 million and research and development expenses of CHF 13.0 million for the same period in 2014. The Company reported a net loss for the nine months ended September 30, 2015 of CHF 24.2 million, or CHF 0.76 per share. This compares to a net loss of CHF 14.2 million, or CHF 0.69 per share, for the same period in 2014.

The increases in operating expenses, and resulting increases in net loss, for the three- and nine-month periods ended September 30, 2015 over the comparable periods in 2014 reflect primarily the progression of the AM-101 Phase 3 clinical development program and preparations for the late stage AM-111 clinical program.

The Company expects its operating expenses for the 2015 financial year to be in line with previous guidance of CHF 30.0 to 35.0 million.

Conference Call / Webcast Information

Auris Medical will host a live conference call and webcast to discuss the Company's financial results and provide a general business update. The call is scheduled for November 12, 2015 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time). To participate in this conference call, dial 1 855 217 7942 (USA) or +1 646 254 3369 (International), and enter passcode 4621688. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at: www.aurismedical.com. A replay will be available approximately two hours following the live call also on the Company's website.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".

Forward-looking Statements

*This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F, the prospectus dated May 14, 2015 relating to its Registration Statement on Form F-1 and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.*

*Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com*
*Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com*

Auris Medical Holding AG
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income (unaudited)
(in CHF thousands, except share and currency data)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|---|---|---|---|
| | 2015 | 2014 | 2015 | 2014 |
| Research and development expenses | (5,884) | (4,686) | (20,865) | (13,036) |
| General and administrative expenses | (1,327) | (998) | (3,237) | (3,552) |
| Operating loss | (7,211) | (5,684) | (24,102) | (16,588) |
| Finance income/(expense), net | 2,000 | 2,323 | (120) | 2,376 |
| Loss before tax | (5,211) | (3,361) | (24,221) | (14,212) |
| Net loss attributable to owners of the Company | (5,211) | (3,361) | (24,221) | (14,212) |
| *Other comprehensive income:* | | | | |
| Items that will never be reclassified to profit or loss: | | | | |
| Remeasurements of defined benefits liability | (4) | 112 | (233) | (312) |
| Items that are or may reclassified to profit or loss: | | | | |
| Foreign currency translation differences | (41) | (74) | 16 | (71) |
| Other comprehensive income | (44) | 37 | (217) | (384) |
| Total comprehensive loss attributable to owners of the Company | (5,255) | (3,323) | (24,438) | (14,596) |
| Loss per share, basic and diluted | (0.15) | (0.14) | (0.76) | (0.69) |
| *Weighted average common shares outstanding, basic and diluted* | *34,290,141* | *24,589,852* | *31,828,984* | *20,488,392* |
| *Currency rate CHF / USD* | *0.9525* | *0.9134* | *0.9507* | *0.8960* |

Auris Medical Holding AG
Condensed Consolidated Interim Statement of Financial Position (unaudited)
(in CHF thousands)

| | September 30, 2015 | December 31, 2014 |
|---|---|---|
| Assets | | |
| *Non-current assets* | | |
| Property and equipment | 247 | 235 |
| Intangible assets | 1,483 | 1,483 |
| Deferred tax asset | - | 33 |
| Total non-current assets | 1,730 | 1,751 |
| *Current assets* | | |
| Current financial assets and other receivables | 576 | 543 |
| Prepayments | 294 | 265 |
| Cash and cash equivalents | 55,401 | 56,934 |
| Total current assets | 56,271 | 57,742 |
| Total assets | 58,001 | 59,493 |
| Equity and Liabilities | | |
| *Equity* | | |
| Share capital | 13,718 | 11,604 |
| Share premium | 112,645 | 93,861 |
| Foreign currency translation reserve | (35) | (51) |
| Accumulated deficit | (76,379) | (52,131) |
| Total shareholders' equity attributable to owners of the Company | 49,949 | 53,283 |
| *Non-current liabilities* | | |
| Employee benefits | 1,759 | 1,411 |
| Deferred tax liabilities | 328 | 360 |
| Total non-current liabilities | 2,086 | 1,771 |
| *Current liabilities* | | |
| Trade and other payables | 2,822 | 3,234 |
| Accrued expenses | 3,143 | 1,205 |
| Total current liabilities | 5,965 | 4,439 |
| Total liabilities | 8,052 | 6,210 |
| Total equity and liabilities | 58,001 | 59,493 |
| *Currency rate CHF / USD* | *0.9739* | *0.8841* |

Auris Medical Holding AG
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income (unaudited)
(convenience presentation in USD thousands, except share data)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|---|---|---|---|
| | 2015 | 2014 | 2015 | 2014 |
| Research and development expenses | (6,042) | (4,812) | (21,424) | (13,386) |
| General and administrative expenses | (1,362) | (1,024) | (3,324) | (3,647) |
| Operating loss | (7,404) | (5,837) | (24,748) | (17,033) |
| Finance income/(expense), net | 2,054 | 2,386 | (123) | 2,440 |
| Loss before tax | (5,351) | (3,451) | (24,871) | (14,593) |
| Net loss attributable to owners of the Company | (5,351) | (3,451) | (24,871) | (14,593) |
| *Other comprehensive income:* | | | | |
| Items that will never be reclassified to profit or loss: | | | | |
| Remeasurements of defined benefits liability | (4) | 115 | (239) | (321) |
| Items that are or may reclassified to profit or loss: | | | | |
| Foreign currency translation differences | (42) | (76) | 17 | (73) |
| Other comprehensive income | (46) | 38 | (222) | (394) |
| Total comprehensive loss attributable to owners of the Company | (5,396) | (3,412) | (25,093) | (14,987) |
| Loss per share, basic and diluted | (0.16) | (0.14) | (0.78) | (0.71) |
| *Weighted average common shares outstanding, basic and diluted* | *34,290,141* | *24,589,852* | *31,828,984* | *20,488,392* |

*Solely for the convenience of the reader, unless otherwise indicated, all Swiss Franc amounts stated in the Condensed Consolidated Statement of Profit and Loss for the 3 and 9 months ended September 30, 2015 and September 30, 2014, have been translated into U.S. dollars at the rate on September 30, 2015 of USD 1.0268 / CHF 1.00. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date.*

Auris Medical Holding AG
Condensed Consolidated Interim Statement of Financial Position (unaudited)
(convenience presentation in USD thousands)

| | September 30, 2015 | December 31, 2014 |
|---|---|---|
| Assets | | |
| *Non-current assets* | | |
| Property and equipment | 254 | 242 |
| Intangible assets | 1,522 | 1,522 |
| Deferred tax asset | - | 34 |
| Total non-current assets | 1,776 | 1,798 |
| *Current assets* | - | |
| Current financial assets and other receivables | 591 | 557 |
| Prepayments | 302 | 272 |
| Cash and cash equivalents | 56,885 | 58,460 |
| Total current assets | 57,779 | 59,289 |
| Total assets | 59,555 | 61,087 |
| Equity and Liabilities | - | |
| *Equity* | - | |
| Share capital | 14,085 | 11,915 |
| Share premium | 115,664 | 96,377 |
| Foreign currency translation reserve | (36) | (52) |
| Accumulated deficit | (78,425) | (53,529) |
| Total shareholders' equity attributable to owners of the Company | 51,288 | 54,711 |
| *Non-current liabilities* | - | |
| Employee benefits | 1,806 | 1,448 |
| Deferred tax liabilities | 336 | 370 |
| Total non-current liabilities | 2,142 | 1,818 |
| *Current liabilities* | - | |
| Trade and other payables | 2,898 | 3,321 |
| Accrued expenses | 3,227 | 1,237 |
| Total current liabilities | 6,125 | 4,558 |
| Total liabilities | 8,267 | 6,376 |
| Total equity and liabilities | 59,555 | 61,087 |

*Solely for the convenience of the reader, unless otherwise indicated, all Swiss Franc amounts stated in the Condensed Consolidated Statement of Financial Position as at September 30, 2015 and December 31, 2014, have been translated into U.S. dollars at the rate on September 30, 2015 of USD 1.0268 / CHF 1.00. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date.*